多靶点泛TRK、ROS1和ALK抑制剂恩曲替尼的安全性与抗肿瘤活性:两项I期试验(ALKA-372-001和STARTRK-1)的合并结果
恩曲替尼是一种口服TRKA/B/C、ROS1和ALK酪氨酸激酶抑制剂,在两项I期研究中评估了晚期或转移性实体瘤患者(包括活动性中枢神经系统疾病)。本文总结总体安全性,并报告携带NTRK1/2/3、ROS1或ALK基因融合、未接受过针对该基因的TKI治疗、且接受达到与推荐II期剂量一致的治疗暴露剂量患者的抗肿瘤活性。恩曲替尼耐受性良好,不良事件主要为1/2级,剂量调整后可逆。在非小细胞肺癌、结直肠癌、乳腺类似分泌癌、黑色素瘤和肾细胞癌中观察到缓解,最早在开始治疗后4周出现,持续时间长达>2年。值得注意的是,一名SQSTM1-NTRK1重排肺癌患者达到完全中枢神经系统缓解。
要点
- 恩曲替尼在携带NTRK1/2/3、ROS1或ALK基因融合的实体瘤患者中耐受性良好,不良事件主要为1/2级。
- 在非小细胞肺癌、结直肠癌、乳腺类似分泌癌、黑色素瘤和肾细胞癌中观察到缓解。
- 一名SQSTM1-NTRK1重排肺癌患者达到完全中枢神经系统缓解。
核心结论
- 恩曲替尼耐受性良好,对携带NTRK1/2/3、ROS1或ALK基因融合的实体瘤具有活性,包括原发性或继发性中枢神经系统疾病患者。
研究设计与样本
- 两项I期研究(ALKA-372-001和STARTRK-1)评估口服TRKA/B/C、ROS1和ALK抑制剂恩曲替尼在晚期或转移性实体瘤患者中的安全性和抗肿瘤活性。
- 分析队列为携带NTRK1/2/3、ROS1或ALK基因融合、未接受过针对该基因的TKI治疗、且接受达到与推荐II期剂量一致的治疗暴露剂量的患者。
主要发现
- 恩曲替尼耐受性良好,不良事件主要为1/2级,剂量调整后可逆。
- 在非小细胞肺癌、结直肠癌、乳腺类似分泌癌、黑色素瘤和肾细胞癌中观察到缓解,最早在开始治疗后4周出现,持续时间长达>2年。
- 一名SQSTM1-NTRK1重排肺癌患者达到完全中枢神经系统缓解。
关键数值与推荐
- 缓解最早在开始治疗后4周出现,持续时间长达>2年。
- 一名SQSTM1-NTRK1重排肺癌患者达到完全中枢神经系统缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naïve to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the recommended phase II dose. Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.Significance: Gene fusions of NTRK1/2/3, ROS1, and ALK (encoding TRKA/B/C, ROS1, and ALK, respectively) lead to constitutive activation of oncogenic pathways. Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease. Cancer Discov; 7(4); 400-9. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 339.
引用
- Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017. PMID: 28183697. doi:10.1158/2159-8290.CD-16-1237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。